<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01670903</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-12-8336-DS-CTIL</org_study_id>
    <nct_id>NCT01670903</nct_id>
  </id_info>
  <brief_title>The Effect of Angiotensin II Type 1 Receptor Antagonists on the Size and Expansion Rate of Abdominal Aortas in Hypertensive Patients</brief_title>
  <official_title>the Effect of Angiotensin II Type 1 Receptor Antagonists on the Size and Expansion Rate of Abdominal Aortas in Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Abdominal aortic aneurysm (AAA) is a common disease that develops from degeneration of the
      aortic wall. The natural history of AAA is gradual expansion and if left untreated may result
      in rupture and death. The mechanism of the development of this disease is unknown however it
      appears to be multifactorial and possibly related to degradation processes within the
      arterial wall. There is growing evidence that Angiotensin receptor blockers ( ARBS) may have
      an inhibitory effect on remodelling processes within the arterial wall, thus inhibiting
      degeneration of the vessel wall.

      Study hypothesis: ARBS are associated with smaller diameters of aortas among hypertensive
      patients, and are associated with a lower rate of aortic expansion compared to other
      antihypertensive drugs.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Aneurysm</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>ARBs</arm_group_label>
    <description>Hypertensive patients treated with ARBs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACE inhibitors</arm_group_label>
    <description>Hypertensive patients treated with ACE inhibitors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non ARB/ACE</arm_group_label>
    <description>Hypertensive patients treated with non ARBs or ACE inhibitors meds</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        medically treated hypertensive patients, ages 50-80
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  medically treated hypertensive patients, ages 50-80

        Exclusion Criteria:

          -  pregnant women

          -  patients previously treated for aortic disease

          -  unable to sign informed consent, minors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Silverberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Silverberg, MD</last_name>
    <phone>035302712</phone>
    <email>Daniel.Silverberg@sheba.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jacob Schneiderman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ehud Grossman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Moshe Halak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anan Younes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dmitry Yakubovitz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bashir Sheik-yosef, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ronnie E Reinitz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Silverberg, MD</last_name>
      <email>Daniel.Silverberg@sheba.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2012</study_first_submitted>
  <study_first_submitted_qc>August 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2012</study_first_posted>
  <last_update_submitted>August 19, 2012</last_update_submitted>
  <last_update_submitted_qc>August 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Daniel Silverberg</investigator_full_name>
    <investigator_title>Senior consultant - Vascular surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensin II</mesh_term>
    <mesh_term>Angiotensinogen</mesh_term>
    <mesh_term>Angiotensin II Type 1 Receptor Blockers</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

